Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.10.18
Views: 771

Prof Dirk Schadendorf - Uniklinik Essen, Essen, Germany

Prof Dirk Schadendorf speaks with ecancer at ESMO 2018 in Munich about the outcomes from the COLUMBUS trial which looked into the use of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma.

Prof Schadendorf explains that for patients receiving encorafenib plus binimetinib there was a median overall survival of 33 months, which was the highest of all the combinations so far.

He also points out the value of the direct comparison between the two B-RAF inhibitors, with encorafenib shown to be clearly superior.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Tobacco Dependence e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation